ArticleBladder (San Francisco, Calif.)2025
Kidney function improvement after urinary diversion for cisplatin eligibility in bladder cancer patients.
Article in Bladder (San Francisco, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Muscle-invasive bladder cancer (MIBC) is an aggressive disease typically treated with radical cystectomy following neoadjuvant chemotherapy (NAC). However, the presence of hydronephrosis - a significant marker of advanced disease - can impair renal function, potentially precluding patients from receiving cisplatin-based NAC. Objective: The present study aimed to assess the role of urinary diversion in patients with MIBC, specifically in reversing renal function impairment and enabling eligibility for cisplatin-based therapy. Methods: A retrospective study was performed by evaluating a database of patients treated for urothelial MIBC from 2018 to 2021. Case notes were reviewed to identify patients with hydronephrosis who underwent urinary diversion. The types of urinary diversion recorded included percutaneous nephrostomy, ureteral stenting, or surgical obstruction release. Renal function was assessed retrospectively using the glomerular filtration rate (GFR), estimated from creatinine clearance. Results: Records of a total of 72 patients were evaluated. The mean GFR before urinary diversion was 44.1 ± 26.4 mL/min, which improved to 59.1 ± 31.9 mL/min post-diversion, resulting in a mean GFR improvement of 15.0 ± 20.0 mL/min. Forty-four patients had an initial GFR below 50 mL/min, with 75% of them achieving a GFR >50 mL/min after urinary diversion. More than half of these patients ( Conclusion: Urinary diversion can benefit patients with upper tract obstruction secondary to MIBC by improving renal function, thereby enabling eligibility for cisplatin-based chemotherapy. Notably, the time to GFR recovery following urinary diversion varied among individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.